Perspectives on the co-treatment with GnRHa in female patients undergoing hematopoietic stem cell transplantation

Cima, Luminiţa; Coliţă, Anca; Fica, Simona

doi:10.1530/ec-17-0246

Cited by 7 publications

(5 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ausência de agentes infecciosos (23)(24)(25)(26)(27) Resposta imunológica eficiente contra células e patógenos (23,(25)(26)(28)(29)(30)(31) Barreiras imunológicas preservadas (32)(33)(34)(35) Antecedentes Adesão ao tratamento medicamentoso (27)(28)34,36) Profilaxia medicamentosa (24)(25)(27)(28)(29)(30)32,37) Técnicas de relaxamento (38) Imunoterapia celular (23,(25)(26)(27)(28)31) Monitoramento imunológico e virológico (24) Vacinas (30) Compatibilidade do HLA (30) Microbiota intestinal presevada (32)(33) Dieta adequada (33) Crioterapia oral (35) Indivíduos imunocompetentes (24)(25)(26)31) Ausência de comorbidades (25,30,…”

Section: Atributosunclassified

“…Ainda em relação à terapia medicamentosa como mecanismo de proteção eficaz, um estudo de 2017 narra que a administração de GnRHa (agonista do hormônio liberador de gonadotrofina), antes do início da quimioterapia padrão, diminui o risco de disfunção gonadal e infertilidade, o que gera proteção ovariana em pacientes submetidas ao transplante. Mulheres que passam pelo tratamento devem ser aconselhadas sobre os benefícios da hormonioterapia (36) .…”

Section: Antecedentesunclassified

“…No tocante à qualidade de vida (QV), evidenciou-se que a trajetória terapêutica tende a reduzir a qualidade de vida dos pacientes. Além disso, o surgimento de complicações decorrentes da debilidade imunológica e os efeitos colaterais da terapia medicamentosa atenuam este fato (26,34,(36)(37) . Outra característica que também compromete o estado de enfrentamento dos pacientes é a fadiga (38) , prevalente durante os primeiros 100 dias após o TCTH (55) .…”

Section: Consequentesunclassified

See 2 more Smart Citations

Proteção ineficaz em pacientes submetidos ao transplante de células-tronco hematopoiéticas: análise de conceito

Oliveira¹,

Silva²,

Perrelli³

et al. 2021

Rev. Eletr. Enferm.

View full text Add to dashboard Cite

Objetivou-se analisar o conceito de “Proteção” em pacientes submetidos ao transplante de células tronco hematopoiéticas e correlacionar com os elementos do diagnóstico de enfermagem “Proteção Ineficaz” proposto pela NANDA-I. Revisão integrativa da literatura, fundamentada no modelo de Análise de Conceito proposto por Walker e Avant. Realizada na Biblioteca Virtual em Saúde e as seguintes bases de dados: CINAHL, SCOPUS, PUBMED/MEDLINE, LILACS e Web of Science com recorte temporal de cinco anos. A amostra final foi composta por 16 artigos e pela identificação de três atributos definidores, 15 antecedentes e 11 consequentes. Conclusão: a análise de conceito pode contribuir para o refinamento e o aprimoramento do diagnóstico de enfermagem “Proteção Ineficaz”. Foi possível identificar uma outra definição, 10 antecedentes e 10 consequentes que não constam na NANDA-I, bem como a necessidade de revisar a definição e demais componentes do diagnóstico propostos pela taxonomia.

show abstract

Section: Atributosunclassified

Section: Antecedentesunclassified

Section: Consequentesunclassified

See 1 more Smart Citation

Proteção ineficaz em pacientes submetidos ao transplante de células-tronco hematopoiéticas: análise de conceito

Oliveira¹,

Silva²,

Perrelli³

et al. 2021

Rev. Eletr. Enferm.

View full text Add to dashboard Cite

show abstract

“…Ovarian suppression using GnRH agonists before and during chemotherapy has not been recommended as standard treatment for patients undergoing HCT 3,5,6 . Mature oocyte cryopreservation before transplantation has been assessed as a method of fertility preservation 1,7–11 . Oocyte or embryo cryopreservation takes approximately 2–3 weeks, which can delay cancer therapy, 11,12 and is not easily performed in many cases due to pancytopenia or decreased organ function following repeated chemotherapies.…”

Section: Introductionmentioning

confidence: 99%

“…3,5,6 Mature oocyte cryopreservation before transplantation has been assessed as a method of fertility preservation. 1,[7][8][9][10][11] Oocyte or embryo cryopreservation takes approximately 2-3 weeks, which can delay cancer therapy, 11,12 and is not easily performed in many cases due to pancytopenia or decreased organ function following repeated chemotherapies. Ovarian failure and early menopause risk factors after HCT have been investigated primarily in pediatric survivors with hematologic malignancies.…”

Section: Introductionmentioning

confidence: 99%

Risk factors of menopause after allogeneic hematopoietic cell transplantation in premenopausal adult women

Lee

Kim

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

Objectives Allogeneic hematopoietic stem‐cell transplantation (HCT) is the only curative option for most hematologic malignancies. However, HSCT can cause early menopause and various complications in premenopausal women. Therefore, we aimed to investigate risk factors predicting early menopause and its clinical implications among survivors post HCT. Methods We retrospectively analyzed 30 adult women who had received HCT at premenopausal status between 2015 and 2018. We excluded patients who had received autologous stem cell transplantation, had relapsed, or died of any cause within 2 years of HCT. Results The median age at HCT was 41.6 years (range, 22–53). Post‐HCT menopause was identified in 90% of myeloablative conditioning (MAC) HCT and 55% of reduced‐intensity conditioning (RIC) HCT (p = .101). In the multivariate analysis, the post‐HCT menopausal risk was 21 times higher in a MAC regimen containing 4 days of busulfan (p = .016) and 9.3 times higher in RIC regimens containing 2–3 days of busulfan (p = .033) than that of non‐busulfan‐based conditioning regimens. Conclusions Higher busulfan dose in conditioning regimens is the most significant risk factor affecting post‐HCT early menopause. Considering our data, we need to decide on conditioning regimens and individualized fertility counseling before HCT for premenopausal women.

show abstract

Long‐term Follow‐up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics

et al. 2020

View full text Add to dashboard Cite

Annually, ~50,000 patients undergo hematopoietic stem cell transplantation (HCT) worldwide with almost 22,000 of these patients receiving HCT in the United States. HCT is a curative option for a wide range of hematologic malignancies, and advances in transplantation medicine have resulted in an increase in HCT survivors. It is anticipated that the number of HCT survivors will more than double from 242,000 in 2020 to ~500,000 in 2030. Survivors of HCT are at an increased risk of developing late complications due to exposure to chemotherapy and/or radiation in the pre‐, peri‐, and post‐HCT phases and these cumulative exposures have the potential to damage normal tissue. This tissue damage leads to the early onset of chronic health conditions resulting in premature mortality in HCT survivors, who have a 15‐year cumulative incidence of severe or life‐threatening chronic health conditions exceeding 40%. Due to the significant burden of morbidity in HCT survivors and the delay in the development of long‐term complications, this delicate patient population requires life‐long monitoring due to the risk for neuropsychological, cardiac, pulmonary, renal, hepatic, ocular, skeletal, cardiac, endocrine, fertility, and sexual health complications, as well as secondary neoplasms. This review will focus on recent advances in screening, monitoring, and therapeutics for late‐occurring or long‐term complications in HCT survivors.

show abstract

Perspectives on the co-treatment with GnRHa in female patients undergoing hematopoietic stem cell transplantation

Cited by 7 publications

References 56 publications

Proteção ineficaz em pacientes submetidos ao transplante de células-tronco hematopoiéticas: análise de conceito

Proteção ineficaz em pacientes submetidos ao transplante de células-tronco hematopoiéticas: análise de conceito

Risk factors of menopause after allogeneic hematopoietic cell transplantation in premenopausal adult women

Long‐term Follow‐up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics

Contact Info

Product

Resources

About